Cardiol Therapeutics Inc Class A faces a notable decline, shedding over 4% in a single trading day.
In the latest trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a significant downturn, closing at CA$1.41, down 4.08%. This decline raises concerns among investors about the company's current market position and future prospects.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$176.37M
52W high
$2.33
52W low
$1.23
1W change
-1.34%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 308.2% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.00
+308.2% Upside
Current Price
C$1.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.5%
Annualized
90-Day Vol
58.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.23
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.39 | C$1.23 โ C$1.57 |
| 60 trading days | C$1.31 | C$1.10 โ C$1.55 |
| 90 trading days | C$1.23 | C$0.99 โ C$1.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Cardiol Therapeutics' developments, especially in light of its recent performance and lack of news that could explain the drop.
Cardiol Therapeutics Inc Class A down 4.08% today
The stock's market cap now stands at approximately CA$176 million, reflecting a challenging environment for the company.
Bull case
Despite today's decline, Cardiol Therapeutics is making progress in its clinical trials. If these trials succeed, they could lead to positive long-term outcomes for the company.
Bear case
The lack of recent positive news or updates from Cardiol Therapeutics raises concerns. This absence suggests that investor confidence may be slipping, which could affect the stock's performance.
Market Reaction
The 4.08% drop in Cardiol Therapeutics' stock price occurred without any significant news or announcements from the company, which usually influences investor sentiment. The market cap now sits at CA$176 million, indicating a challenging environment for the company amid investor uncertainty.
Future Considerations
While the stock has faced a setback today, investors should keep an eye on upcoming developments, particularly regarding the company's clinical trials and research updates. The lack of recent positive news could be a contributing factor to today's decline, making it essential for investors to stay informed.
Investor Sentiment
The current sentiment surrounding Cardiol Therapeutics appears cautious. With no recent announcements to bolster investor confidence, the stock's performance may continue to be volatile. Investors should assess their positions carefully and consider the potential risks involved.
Advertisement
